Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Johnson & Johnson to acquire Atraverse Medical
The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.
Heart Rhythm 2026: Electrophysiologist Mina Chung discusses CPR, PFA and much more
Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.
Women live longer after TAVR than men
Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
FDA approves next-gen mitral valve from Medtronic
The Mosaic Neo mitral bioprosthesis can be implanted through sternotomy, minimally invasive cardiac surgery or robotic access.
PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026
Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends.

Johnson & Johnson to acquire Atraverse Medical

The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.

HRS President, Mina Chung, MD, FHRS, staff cardiologist and Professor of Medicine in the Section of Pacing and Electrophysiology, Heart & Vascular Institute, Cleveland Clinic. Explains HRS accomplishments in the past year in terms of advocacy efforts and policy concerns impacting EP. #HRS2026 #EPeeps

Heart Rhythm 2026: Electrophysiologist Mina Chung discusses CPR, PFA and much more

Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.

Women live longer after TAVR than men

Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.

FDA approves next-gen mitral valve from Medtronic

The Mosaic Neo mitral bioprosthesis can be implanted through sternotomy, minimally invasive cardiac surgery or robotic access.

Heart Rhythm 2026 Program Chair Dhanunjaya "DJ" Lakkireddy, MD, MBA, FHRS, Executive Medical Director, Kansas City Heart Rhythm Institute, and professor of medicine at the University of Kansas Health System, offers an overview of key trends in electrophysiology (EP) technology.

PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends.

Michigan has become the 20th state to opt out from federal regulations that require physician supervision of certified registered nurse anesthetists (CRNAs). The move was made to ensure access to value-based, high-quality care across the state, but it is being opposed by the Michigan Society of Anesthesiologists (MSA) and several other physician groups. Image from the American Association of Nurse Anesthesiology (AANA)

FTC settles antitrust lawsuit against private equity-backed anesthesiology chain

Federal regulators alleged that U.S. Anesthesia Partners—a portfolio company of Welsh, Carson, Anderson & Stowes—engaged in a “roll-up scheme” in Texas that effectively eliminated the competition. The company denies the allegations, but has agreed to undisclosed terms that would see the lawsuit resolved.

IV fluids recalled over possible contamination—patients face risk of vascular complications

Particulate matter may be present in certain 1-liter containers of B. Braun Medical's Lactated Ringer's Injections. If this enters a patient's circulatory system, it could lead to a series of adverse events.

FDA warns public about vascular device after 3 deaths

The FDA is still investigating this issue. For now, the agency recommends considering alternative treatment options when possible.